Middle Tennessee Research Institute

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

Christopher J Edwards, Francisco J. Blanco, Jeffrey Crowley et al. · Annals of the Rheumatic Diseases · 2016 · 283 citations · Full text

Medicine, Dermatology, Pharmacotherapy +15

Gene Profiling of Keloid Fibroblasts Shows Altered Expression in Multiple Fibrosis-Associated Pathways

Joan C. Smith, Braden Boone, Susan R. Opalenik et al. · Journal of Investigative Dermatology · 2007 · 169 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +16

Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial

Alvin F. Wells, Christopher J Edwards, Alan Kivitz et al. · Lara D. Veeken · 2018 · 100 citations · Full text

Life Sciences, Pharmacotherapy, Autoimmunity +15

Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)

Peter Nash, Kamal Ohson, Jessica A. Walsh et al. · Annals of the Rheumatic Diseases · 2018 · 88 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +16

Efficacy and Safety of <scp>ABBV</scp>‐3373, a Novel Anti–Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody–Drug Conjugate, in Adults with <scp>Moderate‐to‐Severe</scp> Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, <scp>Double‐Blind</scp>, <scp>Active‐Controlled Proof‐of‐Concept</scp> Phase <scp>IIa</scp> Trial

Frank Buttgereit, Jacob Aelion, Bernadette Rojkovich et al. · Arthritis & Rheumatology · 2022 · 53 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17